Since single GIP receptor agonism also demonstrated neuroprotective properties [138,139] and incretin-based multi-agonists have been shown to inhibit neurodegeneration in cellular models [140], these newly developed agents are suitable candidates as AD therapies. The gene discussed is GCG; the disease is Alzheimer disease.